Emmanuelle Papot
Overview
Explore the profile of Emmanuelle Papot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papot E, Tovar-Sanchez T, Woods J, Thaurignac G, Eriobu N, Borok M, et al.
AIDS
. 2024 Nov;
39(4):448-456.
PMID: 39576151
Objective: Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies...
2.
Dharan N, Sasson S, Ahlenstiel G, Andersen C, Bloch M, Buckland G, et al.
PLoS One
. 2023 Nov;
18(11):e0289907.
PMID: 37910527
People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to collate data on this heterogenous population. We conducted...
3.
Jordans C, Vasylyev M, Rae C, Jakobsen M, Vassilenko A, Dauby N, et al.
Euro Surveill
. 2023 Jan;
27(48).
PMID: 36695464
BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided...
4.
Papot E, Jacoby S, Arlinda D, Avihingsanon A, Azwa I, Borok M, et al.
HIV Res Clin Pract
. 2022 Aug;
23(1):37-46.
PMID: 35938597
A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. DEFT is an...
5.
Papot E, Kaplan R, Vitoria M, Polizzotto M
AIDS
. 2021 Dec;
35(Suppl 2):S153-S163.
PMID: 34848582
No abstract available.
6.
Papot E, Kalampalikis N, Doumergue M, Pilorge F, Quatremere G, Yazdanpanah Y, et al.
BMJ Open
. 2021 Nov;
11(11):e046212.
PMID: 34836895
Objective: The aim of this study was to evaluate people living with HIV (PLWH) and HIV specialist prescribers' perception of discussing antiretroviral therapy (ART) price in PLWH's care and the...
7.
Cortier M, de La Porte C, Papot E, Goudjo A, Guenneau L, Riou F, et al.
Travel Med Infect Dis
. 2021 Oct;
46:102180.
PMID: 34699955
Background: Europe lacks studies related to asylum-seekers' health. Methods: We described the health status, healthcare and follow-up of men seeking asylum, accommodated in a primary reception center in Paris (CPA)....
8.
Fournier A, Parienti J, Champenois K, Feret P, Papot E, Yazdanpanah Y, et al.
PLoS One
. 2020 Oct;
15(10):e0240417.
PMID: 33057366
Objectives: The aim of our study was to identify HIV-positive patients at risk of medical care interruption (MCI) in a provincial city of a high-income country. Methods: We estimated the...
9.
Couffignal C, Papot E, Etienne A, LeGac S, Laouenan C, Beres D, et al.
AIDS Care
. 2019 Aug;
32(7):811-817.
PMID: 31431047
We evaluated awareness of treatment as prevention (TasP) among adults people living with HIV (PLHIV) in five infectious disease departments in Paris, then how they perceived its impact on their...
10.
Fournier A, Yazdanpanah Y, Verdon R, Lariven S, Mackoumbou-Nkouka C, Phung B, et al.
PLoS One
. 2019 Mar;
14(3):e0213526.
PMID: 30865722
Objectives: With HIV treatment as a prevention strategy, retention in care remains a key for sustained viral suppression. We sought to identify HIV-infected patients at risk for medical care interruption...